Clinical trials: LDL-C
Dyslipidemia
The Effect of 3-Week Consumption of Soya Beverage Enriched With Plant Sterols on Serum LDL-C
This is a local, single-center, two-arm, randomized, double-blind, placebo-controlled clinical trial that examines the LDL-C-lowering effect of the consumption of a soya beverage enriched with plant sterol for 3 weeks.
- Trial name
- NCT02881658
- Testing
- Plant sterols-enriched soya beverage provided by Vitasoy, Soya beverage provided by Vitasoy
- Where
- Hong Kong
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Pharmacokinetics and Pharmacodynamics Study
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.
- Trial name
- NCT07074236
- Testing
- QLC7401 injection, RBD7022 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
This clinical trial has two parts. In Part A, the goal is to learn about the safety and tolerability of COR-2003 when it is given alone.
- Trial name
- NCT07858019
- Testing
- COR-2003, COR-1004 + COR-2003
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Cardiovascular Diseases, Lipid Disorder
SRMA of the Effect of Soy Milk vs Cow's Milk on Cardiometabolic Outcomes
Dairy consumption has shown associations with decreased incidence of cardiometabolic diseases. With the growing interest in plant-based eating, and the mounting evidence for the cardiovascular benefits of plant forward diets…
- Conditions
- Cardiovascular Diseases, Lipid Disorder, Metabolic Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05637866
- Testing
- Soy milk
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Lipoprotein Metabolism, PCSK9
Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults
Background: Metabolism is what the body does to turn food into energy. Omega-3 fatty acids are substances found in foods such as cold-water fish and shellfish that are essential for good health.
- Conditions
- Lipoprotein Metabolism, PCSK9, Proteomics
- Trial name
- NCT02514070
- Testing
- EPA-rich fish oil, DHA-rich fish oil
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases
Study Into Genetic Influence on Cholesterol Response to Dietary Fat
Cardiovascular disease (CVD) is recognised as one of the main causes of death in the western world. LDL- cholesterol ('bad' cholesterol) and other lipids (fats) are important CVD risk factors.
- Trial name
- Satgene (NCT01384032)
- Testing
- Low fat diet, Hgih saturated fat diet, High saturated fat diet
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Reading
Hypercholesterolemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.
AZD8233 has not been evaluated in clinical studies previously. This is a first-in-human (FiH) study. This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD8233, following subcutaneous (SC) administration…
- Trial name
- NCT03593785
- Testing
- AZD8233
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolemia
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
- Trial name
- NCT01979601
- Testing
- LGT209
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy
- Trial name
- NCT03427710
- Testing
- CiVi007
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Civi Biopharma, Inc.
Healthy Volunteers
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body…
- Trial name
- NCT01618916
- Testing
- LY3015014
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cholesterol Variability, Trained Immunity
LDL-c Level Variability and Trained Immunity
Statin treatment significantly reduces the incidence of cardiovascular events. However, cholesterol variability is associated with the risk of adverse events such as mortality, myocardial infarction, and stroke.
- Trial name
- NCT05790499
- Testing
- Atorvastatin
- Where
- China
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Healthy Participants
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels
The purpose of this study is to evaluate pharmacodynamics (PD) of AZD0780 compared with placebo by assessment of low-density lipoprotein-cholesterol (LDL-C) levels following repeated oral dosing in healthy adults with elevated…
- Trial name
- NCT07423598
- Testing
- AZD0780
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolemia, Vitamin D Deficiency
Effects of Vitamin D on Lipids
The purpose of this study is to examine whether oral vitamin D supplementation in people with inadequate vitamin D concentrations will lower LDL-cholesterol and total cholesterol concentrations.
- Trial name
- NCT00723385
- Testing
- Vitamin D (1000 or 2000 IU/day)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hypercholesterolemia, Breast Cancer
Plant Sterol INtervention for Cancer Prevention (PINC)
Several types of human cells convert cholesterol into other molecules, including oxysterols. Oxysterols can promote breast cancer growth and help tumours to spread.
- Conditions
- Hypercholesterolemia, Breast Cancer, Obesity
- Trial name
- PINC (NCT04147767)
- Testing
- Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd), Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Leeds
Cardiovascular Diseases
Meta-analysis of 46 FDA Identified Studies on Lipid Markers
The FDA have revised the data on soy and concluded that a heart health claim is no longer justified based on more recent studies. They are allowing and established panel for public input.
- Trial name
- NCT03468127
- Testing
- Soy foods
- Where
- 2 sites in Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Healthy, NAFLD
Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
This study is to evaluate the effect of food on the pharmacokinetics of a single dose of ASC41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of Tmax, Cmax, AUC0-t, AUC0-∞.
- Conditions
- Healthy, NAFLD, Hyperlipidemia
- Trial name
- NCT04692025
- Testing
- ASC41 tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Overweight; Hyperlipidemia
Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects
Barley, like oats, is a rich source of the soluble fibre β-glucan, which has been shown to significantly lower LDL-cholesterol (LDL-C). However, barley foods have been less widely studied.
- Trial name
- NCT01402128
- Testing
- Barley beta-glucan(3.0g)
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Hypercholesterolemia, Familial
Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)
This is a 105-week clinical study in patients with heterozygous familial hypercholesterolemia on intensive Low Density Lipoprotein-cholesterol (LDL-C) lowering therapy intended to assess the affects of MK0524A on carotid intima…
- Trial name
- ACHIEVE (NCT00384293)
- Testing
- Comparator: niacin (+) laropiprant (MK0524A)
- Volunteers
- 937 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
- Trial name
- NCT06742853
- Testing
- AZD0780, Ezetimibe, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.